COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Topical Alprostadil for Female Sexual Arousal Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00324948
Recruitment Status : Completed
First Posted : May 11, 2006
Last Update Posted : March 10, 2009
Information provided by:

Brief Summary:
Approximately 300 patients with female sexual arousal disorder who meet eligibility criteria will be enrolled and randomized to receive either active drug or matching placebo. After a two-month, non-treatment period, patients will receive study drug for 6 months and will record information about sexual encounters in a daily diary. Study drug will be applied directly to the genital area 30-60 minutes before initiation of sexual activity. The endpoint of the study is based on the use of a standard measure of sexual function (FSEP).

Condition or disease Intervention/treatment Phase
Sexual Dysfunction, Physiological Drug: Topical alprostadil (PGE-1) Phase 2

Detailed Description:
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-design study involving about 300 women who are 21-60 years of age inclusive, who have undergone a hysterectomy (with or without oophorectomy), and who have a primary diagnosis of FSAD. The diagnosis of FSAD will be made based on a medical and sexual history and confirmed using a structured interview by trained personnel. Study subjects will undergo a 2-month non-treatment run-in period followed by a 6-month period of blinded study therapy. Study drug is applied topically to the genitalia 30-60 minutes prior to initiation of sexual activity. Study subjects will complete several questionnaires at various times during the study and will complete a daily diary. The study endpoint is based on the FSEP and other standard questionnaires, as well as safety and tolerability of study drug.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, 6-Month Evaluation of the Safety and Efficacy of Topical Alprostadil in Hysterectomized Women With Female Sexual Arousal Disorder (FSAD)
Study Start Date : September 2004
Actual Primary Completion Date : August 2006
Actual Study Completion Date : November 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Alprostadil

Primary Outcome Measures :
  1. FSEP

Secondary Outcome Measures :
  1. FSFI
  2. Global assessment
  3. Adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women aged 21-60 who have undergone a hysterectomy
  • Have a primary diagnosis of female sexual arousal disorder
  • Be willing to comply with all study requirements and visit schedules

Exclusion Criteria:

  • Known allergy to alprostadil or product excipients
  • Have a genital inflammatory or infectious condition or STD
  • Have a significant medical condition that would interfere with the study
  • Have received an investigational drug within the prior 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00324948

Layout table for location information
United States, California
Stanford University School of Medicine-Dept of OB/GYN
Stanford, California, United States, 94305
United States, Ohio
Radiant Research
Cincinnati, Ohio, United States, 95249
Sponsors and Collaborators
Layout table for investigator information
Study Director: Sam Teichman, MD Vivus Clinical Research Department
Layout table for additonal information
Responsible Party: Wesley Day, VP Clinical, Vivus, Inc. Identifier: NCT00324948    
Other Study ID Numbers: Vivus-FSD-10
First Posted: May 11, 2006    Key Record Dates
Last Update Posted: March 10, 2009
Last Verified: March 2009
Keywords provided by VIVUS, Inc.:
Female sexual arousal disorder
Female sexual dysfunction
Additional relevant MeSH terms:
Layout table for MeSH terms
Sexual Dysfunction, Physiological
Sexual Dysfunctions, Psychological
Mental Disorders
Genital Diseases, Male
Genital Diseases, Female
Platelet Aggregation Inhibitors
Vasodilator Agents
Urological Agents